English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Prothrombin time ( PT ) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic ( PK ) data to provide individual exposure measures for input into rivaroxaban exposure–response analyses, the aim of the present study was to investigate the use of  PT ‐adjustment approaches (i.e., the use of observed individual  PT  measurements) to enhance the prediction of individual rivaroxaban exposure metrics (derived using a previously developed integrated population  PK  model) based on the observed linear relationship between  PT  and rivaroxaban plasma concentrations. The  PT ‐adjustment approaches were established using time‐matched  PK  and  PT  measurements, which were available from 1,779 patients across four phase II trials and one phase III trial of rivaroxaban.  PT ‐adjusted exposure estimates improved the identification of statistically significant effects when compared with covariate‐only exposure estimates.

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling